Insulin microinjection into the nucleus tractus solitarii of the rat attenuates the baroreceptor reflex. 1996

A M McKernan, and F R Calaresu
Department of Physiology, University of Western Ontario, London, Canada.

The presence of insulin and insulin binding sites in the central nervous system and the demonstration that central insulin has an effect on cardiovascular function has led to the hypothesis that insulin may play a role in mediating the baroreceptor reflex. To investigate this possibility, insulin was microinjected into depressor sites in the nucleus tractus solitarius (NTS), the first central synapse of the baroreceptor reflex, of urethane anesthetized rats. Microinjection of insulin into the NTS (110 nL of 1, 10 and 100 IU/mL) did not change mean arterial pressure (MAP) or heart rate (HR). However, insulin microinjection attenuated phenylephrine-elicited reflex bradycardia and depressor responses elicited by glutamate (GLU). The attenuation of GLU-elicited depressor responses was time-dependent for MAP changes and time and concentration-dependent for HR changes (p < 0.05). Insulin-like growth factor-1 microinjection into the NTS also attenuated GLU-elicited decreases in MAP (p < 0.05) but not HR. The effect of insulin on GLU-elicited responses was inhibited after peripheral adrenergic blockade by nadolol (1.0 mg/kg i.v.) but not after cholinergic blockade by methyl-atropine (2.0 mg/kg i.v.). These results demonstrate that insulin inhibits baroreceptor reflex responses in the NTS likely through an influence on the effects of excitatory amino acid neurotransmitters on the activity of NTS neurons involved in sympathetic control of the cardiovascular system.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008297 Male Males
D008845 Microinjections The injection of very small amounts of fluid, often with the aid of a microscope and microsyringes. Microinjection
D009248 Nadolol A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor. Corgard,SQ-11725,Solgol,SQ 11725,SQ11725
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D010656 Phenylephrine An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent. (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol,Metaoxedrin,Metasympatol,Mezaton,Neo-Synephrine,Neosynephrine,Phenylephrine Hydrochloride,Phenylephrine Tannate,Neo Synephrine,Tannate, Phenylephrine
D001919 Bradycardia Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK. Bradyarrhythmia,Bradyarrhythmias,Bradycardias
D002319 Cardiovascular System The HEART and the BLOOD VESSELS by which BLOOD is pumped and circulated through the body. Circulatory System,Cardiovascular Systems,Circulatory Systems

Related Publications

A M McKernan, and F R Calaresu
February 1988, Hypertension (Dallas, Tex. : 1979),
A M McKernan, and F R Calaresu
January 2010, American journal of physiology. Regulatory, integrative and comparative physiology,
A M McKernan, and F R Calaresu
February 1988, Hypertension (Dallas, Tex. : 1979),
A M McKernan, and F R Calaresu
November 2008, Autonomic neuroscience : basic & clinical,
A M McKernan, and F R Calaresu
July 1985, European journal of pharmacology,
Copied contents to your clipboard!